ABOUT:
Focusing on early stage innovation

LinkEdge invests seed capital in genuine life sciences innovation from Israeli universities, research institutions and medical centers. We use our expertise to navigate early ventures closer to their goals. The platform was established by two synergetic players: Medison Pharma, a leading commercial partner for international pharma companies in Israel, and Zavit Ventures, an active investor in Israeli biotech and next-generation technologies.

Unmet need:
The funding gap for early stage ventures

Early stage life science innovations suffer from a funding gap – they have exhausted the resources available to them but have not created sufficient value to secure significant financing from investors. This often causes them to make commercialization and licensing deals that are not in their best interest.

Unmet need:
The funding gap for early stage ventures

Early stage life science innovations suffer from a funding gap – they have exhausted the resources available to them but have not created sufficient value to secure significant financing from investors. This often causes them to make commercialization and licensing deals that are not in their best interest.

Strategy:
Investing in evolutionary and
revolutionary ventures

Our goal is to work closely with institutions that foster innovation, seeking projects in the ideation stage or in initial development that are underlined by evolutionary or revolutionary innovative premises. With a strong emphasis on drug development, medical devices, and digital health, we aim to capitalize on the funding gap in early stages building value over time.

LinkEdge: Addressing the funding gap
1
01
knowledge

About half of the IP in dozens of
Technology Transfer Offices (TTOs) in Israel is life science-related

02
gap

Many TTOs lack funding and have limited ability to assess projects with healthcare industry perspective

03
growth

LinkEdge’s smart funding complements capital with commercialization support through its partners’ capabilities

investors:
An opportunity to gain access to Israeli technology
1

LinkEdge provides a platform for investing in a diverse set of technologies and IP under one roof—an opportunity for investors seeking additional areas of growth.

Our essence is smart funding: We offer financial support to projects and couple it with the benefits of the fund’s affiliation with the Medison Group, which includes access to a global industry with vast internal know-how.

Team

1
goozy
Goozy hartog
Dr. Hartog is LinkEdge’s managing partner. Goozy completed his neurobiology Ph.D. at New York College and joined the Solution Lab to support young biotech companies through commercialization. His next position was with the Boston Consulting Group where he worked as a consultant on multiple pharma and finance-oriented projects for multinational companies. As part of the Corporate Development Manager at Medison Pharma, Goozy is managing collaborations, forming partnerships and assessing investment opportunities.
nadav
Nadav Kidron
Mr. Kidron is a Partner in LinkEdge and a senior advisor. Mr. Kidron is the CEO of Oramed Pharmaceuticals, which he co-founded in 2006. During his tenure, he co-founded Entera Bio (drug delivery platform) as a JV with DNA Biomedical Solutions. Mr. Kidron fulfilled senior executive roles in a variety of industries, is a IATI board member, and an international lecturer on Israel’s entrepreneurial culture.
amiad
Amiad Solomon
A Serial entrepreneur and early-stage investor in multiple startups pharma, medical devices, and MedTech, Mr. Solomon is a Partner in LinkEdge, charged with leading investor relations and strategy.  Previously Mr. Solomon was a Venture Partner at Sequoia Capital and is a sought after Speaker and Author with articles published in media outlets as The Huffington Post and the WSJ. Early in his career, Mr. Solomon was a Sales and BD Executive at IDX Health (acquired by GE).
Meet our partners:
Power through collaboration
1
CONTACT:
TTOs, Inventors, Investors: Get in touch!